GNSL: ein chart zum liebhaben - 500 Beiträge pro Seite

[Mattek]

Genomic Solutions z.Z. u.a wegen charttechnik (nasdaq) hochinteressant.

1. Doppeltief um 13 $, gestern in usa + 0,4 %; heute + 2,5 %
2. Fast und Slow Stochastik drehen gen norden
3. RSI < 30


Break even wird ende 2001 erreicht sein.

ansonsten bitte gnc-thread.

Kauf für morgen mit limit 16 € in fse empfehlenswert. beobachte gnsl seit ipo im mai. würde mich schwer verschätzen, wenn in usa bis freitag weniger als + 10 % rausspringen.

viel erfolg
mattek

[Mattek]

bitte schön:

+ 12 %

danke schön
mattek

[Mattek]

Schluss mit + 13,73 % bei 14 1/2 USD

nun, meine erste prognose passte. ich vergleiche die entwicklung nach dem ersten tief bei 13 USD am 22.08.00.

jetzt wird es einfach: Montag Kauf in FSE bei Limit 16,20 €. erwarte zwei Wochen später 22 €.

top, die wette gilt.

der gnsl-erfahrene
mattek

[to2300]

siehe auch Thread von Giggas!

GNSL sieht technisch einfach geil aus!

Dann mal los!

to2300

[joiner]

@mattek
Charttechnik ist aber nicht immer alles !
Welche Gründe sprechen außerdem für GS ?
Warum der steile Abstieg ?
Bin nicht ganz überzeugt von diesem Titel.
Greetings, Joiner

[Mattek]

@ joiner:

Chart läuft weiterhin. Gebe dir absolut recht, dass charttechnik - gerade im biotech-bereich - nicht alles ist. mir ging es aber hier um die kurzfristige chance. die wir weiterhin voll genutzt.

aktuell: 17 7/16 $

langfristig sowieso interessant. siehe hierzu diverse threads.

happy trade
mattek

[Mattek]

@ gnsl-investierte, man muss sich auch melden, wenn`s nicht so läuft.

schade, scheint lediglich der von mir angesprochene charttechnisch-begründtete anstieg gewesen zu sein. hinzu kommt das "prima" bio- und nasdaq-klima.

bin selbstverständlich (inwischen ohne not !) weiter investiert. ist halt letztendlich ein sogenannter long-term-buy.

sehr gespannt auf montag ! umsatz ist weiterhin ansehnlich.

meinungen erwünscht.

gruß
mattek

[to2300]

Hier die letzten News!

Genomic Solutions to Collaborate with Major Mass Spectrometer
Companies

ANN ARBOR, Mich., Oct. 6 /PRNewswire/ -- Genomic Solutions Inc. (Nasdaq: GNSL - news), a leading, worldwide supplier of automated solutions for genomic
and proteomic research, announces it is designing its Investigator Proteomic System to integrate, via both hardware and software, with mass spectrometers from all
major manufacturers.

``Data from a mass spectrometer is an integral part of protein characterization,`` says Christine Ethier, Genomic Solutions` Vice President -- Proteomics. ``We feel
this strategic decision within our Proteomics Business Unit is the most effective way we can give customers the flexibility they need, while enabling our Investigator
Proteomics System to integrate seamlessly into their established mass spec protocols.``

Supporting that strategy, Genomic Solutions` newest product, Protein Warehouse(TM), integrates all current Investigator component data from the company`s
individual proteomics instruments. These include 2D electrophoresis system, gel processor, automated stainer, image acquisition system, ProPic(TM) fluorescent
automated protein spot excision robot, ProGest(TM) digestion station, and ProMS(TM) MALDI preparation station.

``With numerous sales worldwide, Investigator has been very successful for automating proteomics,`` Ethier adds. ``We wish to continue that rapid market
penetration by assuring prospective customers of compatibility and full integration into their current or future mass spec systems. We`re giving customers freedom of
choice, rather than forcing them to discontinue use of their current mass spec because they must buy one from a single vendor if they wish to have an integrated
system. Customers can have the peace of mind in knowing that our Investigator system will integrate with any MALDI, LC/MS/MS or ion trap mass spec from any
of the major manufacturers.``

Genomic Solutions will now focus its resources on future improvements and additions to the Investigator Proteomic System. These will include additional
consumables, reagents, hardware, software and separation technologies to further enhance customers` ability to conduct high-throughput proteomics, rather than
focusing resources on entering the MALDI market with our own mass spectrometer.

As a result of this strategy modification, Genomic Solutions has divested its MALDI-TOF project and intellectual property to Thermo Electron in exchange for an
undisclosed amount of cash and other considerations. Thermo Electron is one of the major mass spectrometer manufacturers that has agreed to work with GSI to
ensure their mass spectrometers integrate with the Investigator Proteomic System.

Genomic Solutions Inc. designs, develops, manufactures, markets and sells instruments, software, consumables and services used to determine the activity level of
genes and to isolate, identify and characterize proteins. The company`s products and systems enable researchers to perform complex, high volume experiments at a
lower cost and in less time than traditional techniques. As a result, Genomic Solutions products and systems facilitate more rapid and less expensive drug discovery.
Genomic Solutions markets products through its corporate headquarters in Ann Arbor, Michigan USA, and offices in the United Kingdom and Japan. Remaining
worldwide distribution is provided by PerkinElmer Life Sciences through a strategic alliance with Genomic Solutions. The two companies also cooperate to sell
co-branded products and collaborate to leverage their intellectual property and technologies.

Statements in this press release that are not strictly historical are ``forward-looking`` statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty that exist in the Company`s operations and
business environment. Such statements are predictions only and actual events or results may differ materially from those projected in such forward-looking
statements. Factors that could affect actual events or results include risks associated with performance under the Company`s agreements with third parties, research
and development progress, competitive products and the strength of the Company`s patent portfolio. These factors and others are more fully described under ``Risk
Factors`` in the Final Prospectus included in the Company`s Registration Statement on Form S-1 (File No. 333-30246) as filed with the Securities and Exchange
Commission and declared effective by the SEC on May 4, 2000.